Absolute Lymphocyte Count at Day 29 of Treatment Is a Powerful Predictor of Outcome in Multiple Myeloma

Absolute Lymphocyte Count at Day 29 of Treatment Is a Powerful Predictor of Outcome in Multiple Myeloma

Micro-Abstract Multiple myeloma is a malignancy of the bone marrow. Despite advances, the overall prognosis remains poor with median survival of 4-5 years. In a retrospective analysis of 38 patients, we find that the day 29 lymphocyte count, measured four weeks after starting treatment, can powerful...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2015-04, Vol.15 (4), p.222-226
Hauptverfasser: Narwani, Vishal, Gabriel, Joseph, Boyd, Kevin, Chevassut, Timothy
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Aged, 80 and over
ALC
ALC-29
Animals
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cyclophosphamide Thalidomide Dexamethasone
Female
Hematology, Oncology and Palliative Medicine
Humans
Kaplan-Meier Estimate
Lymphocyte Count
Male
Middle Aged
Multiple Myeloma - blood
Multiple Myeloma - mortality
Multiple Myeloma - therapy
Prognosis
Retrospective Studies
Survival
Time Factors
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Micro-Abstract Multiple myeloma is a malignancy of the bone marrow. Despite advances, the overall prognosis remains poor with median survival of 4-5 years. In a retrospective analysis of 38 patients, we find that the day 29 lymphocyte count, measured four weeks after starting treatment, can powerfully predict prognosis. This simple test can guide optimal management and yields insights into the disease.
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2014.10.002